(Reuters) – The U.S. Food and Drug Administration has approved more than 30 new drugs since January. To date, five drugs have had their commercial launch delayed by manufacturers until later in the year or 2021 due to the COVID-19 pandemic.
Here are the drugs that have been delayed:
Aimmune Therapeutics Inc (AIMT.O) has suspended the launch of the first peanut allergy treatment to be approved by U.S. regulatory authorities until later this year due to the widespread closure of allergist practices. It is the company’s only approved product, which means that Amimmune is unlikely to realize the $ 48 million in annual revenue that some analysts had previously forecast.
Neurocrine Biosciences Inc (NBIX.O) has delayed the launch of its treatment for Parkinson’s disease, which analysts are expected to generate nearly $ 9 million in its first year, until later this year, in part because that he said neurologists have been busy helping to treat patients with COVID-19. .
Endo International PLC (ENDP.O) delayed the launch of its drug Xiaflex as a cellulosic treatment until later in 2020, although the FDA will have to issue a formal verdict on its approval in July. Xiaflex earned $ 89 million in the first quarter of 2020 for use in other conditions, such as painful erections. Endo executives told Reuters they expect a wave of patients to start taking new prescription drugs once the social distancing measures have ended.
Sanofi SA (SASY.PA) launched its treatment for multiple myeloma, Sarclisa, in March, but then suspended the ramp-up and postponed full commercialization until the COVID-19 pandemic subsided. Analysts predicted the drug would earn $ 173 million in its first year.
This treatment for relapsing multiple sclerosis was approved in late March and some analysts expected to earn up to $ 91 million in 2020. Bristol Myers Squibb Co (BMY.N) delayed the product, citing a slowdown in new drugs started in the early days of the pandemic, but it progressed with the launch in June because “doctors are starting to actively launch new therapies,” said business director Christopher Boerner in a recent call to investors .